Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy

Abstract

BackgroundThe quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand the QoL of patients undergoing treatment for OS to improve the QoL. We report on the first prospective international QoL study that was embedded within a large randomized clinical trial from 4 national study groups.ObjectiveThis paper aimed to describe the QoL study development, methodology, accrual details, and characteristics of the QoL cohort.MethodsA total of 2260 patients registered in the EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1), of whom 97.92% (2213/2260) were eligible for the optional QoL assessment and could participate in terms of questionnaire availability. Overall, 61.86% (1369/2213) of patients and/or proxies completed the QoL evaluation at the first assessment time point (E1) after the start of preoperative treatment. The QoL measures used (self- and/or proxy reports) depending on the patient’s age and national study group. Participants and nonparticipants in the ancillary QoL study were compared regarding relevant demographic and disease-related characteristics at registration in the trial.ResultsThe participation rate at time point E1 did not differ with regard to age, gender, the occurrence of pathological fracture, or the presence of any metastases at diagnosis. No differences were found regarding the primary tumor site. Only the national study group affiliation had an influence on participation. Participation decreased linearly with trial progress up to 20% at the final time point of QoL assessment.ConclusionsThis study demonstrates the feasibility of international cooperation for the purpose of assessing and understanding the QoL of pediatric and adolescent/young adult patients with cancer. Future outcomes of this QoL substudy will help to adapt interventions to improve QoL.

Immunohistochemical Study of Histone Protein 3 Modification in Pediatric Osteosarcoma Identifies Reduced H3K27me3 as a Marker of Poor Treatment Response

“…The histologic morphologies seen in our patient cohort also follow the expected distribution with the osteoblastic morphology (Fig. 1A,B) being the most common in 70.6% of patients [23]. Lastly, the outcomes in our patient cohort is consistent with literature, where we found that nearly 70% of patients had a favorable 5-year overall survival and patients with only localized disease had superior survival outcomes (p=0.0058) [12].…”

Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma

“…The overall study design [ 25 , 26 ] and the methodological specifics of the QoL questionnaire sub-study have been laid out in detail previously [ 27 ]. We briefly describe the study design.…”

“…The EURAMOS-1 trial cohort consisted of 2260 participants who, between the ages 5 and 40 years old, had been diagnosed with a previously untreated resectable high-grade osteosarcoma (at any site, except for craniofacial structures). Among these, 2213 participants were eligible for QoL-assessment (≥5 years old) and had a questionnaire in their respective language available (see [ 27 ]). Recruitment took place between 2005 and 2011, involving 17 countries and four study groups: the Children's Oncology Group (COG), the Cooperative Osteosarcoma Group (COSS), the European Osteosarcoma Intergroup (EOI), and the Scandinavian Sarcoma Group (SSG).…”

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

“…Negative occurrences such as nausea and vomiting, hepatotoxicity, anemia, neutropenia, and thrombocytopenia were discovered to be widespread in pediatric osteosarcoma patients enduring chemotherapy [13]. Factors linked with chemotherapy-induced liver toxicity comprised of increased chemotherapy quantities, elevated plasma methotrexate levels, and a more gradual pre-hydration velocity [31]. The quality of life of patients undergoing treatment for osteosarcoma was assessed in a prospective international study, which found that the disease itself and the treatment applied to the patients may negatively impact the patients quality of life [5].…”